Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BIOCRAFT SAYS FY 1986 NET EARNINGS WILL RISE 34% TO $6 MIL. MARK; FOURTH QUARTER EARNINGS DROP 40% HOWEVER; BIOGEN FIRST QUARTER REVENUES OFF 21%

Executive Summary

Biocraft is expecting a 34% increase in fiscal 1986 net earnings to $6 mil., the generic mfr. announced in a May 8 press release. Subject to final audit completion, sales will be in the $43 mil. range, reflecting a 25% increase over 1985 levels. "This is notable," commented Biocraft Chairman Harold Snyder, "considering that we elected to spend an additional $1 mil. in the 1986 fiscal year on R&D efforts -- investing over four percent of sales in R&D rather than the 2.3% invested in the prior year." For the fourth quarter, however, Biocraft indicated it will report a nearly 40% drop in net income to approximately $1 mil. on sales of roughly $9.7 mil. Fourth quarter volume was "marginally ahead" of fourth quarter 1985 levels, the company said. The release noted that fourth quarter earnings were affected by expenditures of $650,000 for new product studies. Announcing its year-end results, Carter-Wallace reported a nearly 19% sales increae to $400.2 mil. for the fourth quarter ended March 31. Net earnings rose 33% to $27.6 mil. during the three-month period. For the fiscal year ended March 31, the company said that sales were up 15% to $112.5 mil., while net earnings jumped nearly 20% to $6.1 mil. Biogen said that its 21.4% first quarter revenue decline to $3.8 mil. resulted from a new licensing strategy. "The first quarter results reflect our decision to seek licensing arrangements that take into account the higher added value of our products," Chairman and CEO James Vincent explained. For the three months ended March 31, Biogen reported a net loss of $6.3 mil., compared to a net loss of about $5 mil. in the first quarter of 1985. Baltimore-based Pharmakinetics reported that third quarter renenues declined 49% to $1.8 mil., however, the company posted net earnings of $116,518, compared to a loss of $1.6 mil. in the third quarter of fiscal 1985. "Though earnings for the third quarter continued a pattern of profitability started in the fiscal first quarter, profits still reflect some residual expenses from the previous year's termination of clinical testing," President Steven Woodman commented. For the nine months ended March 31, Pharmakinetics reported revenues of $5.8 mil., off 38.2% from the first three quarters of fiscal 1985. The company had net earnings of $297,603 during the period, compared to a net loss of $7.6 mil. the previous year. Chart omitted.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel